News

December 1, 2020

StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”

July 9, 2020

Jerusalem Post – Sheba Launches World’s First ‘Reversed Personalized Medicine’ Cancer Trial

December 31, 2018

Journal of Translational Medicine: “Unleashing Endogenous TNF-alpha as a cancer immunotherapeutic”

Immunicom Inc.

HEADQUARTERS

San Diego, CA

6048 Cornerstone Ct W
Suite D
San Diego, CA 92121

RESOURCES

Terms of Use

Privacy policy

GET IN TOUCH

Contact us

Immunicom’s Immunopheresis TM therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe.

News

StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”

Jerusalem Post – Sheba Launches World’s First ‘Reversed Personalized Medicine’ Cancer Trial

Journal of Translational Medicine: “Unleashing Endogenous TNF-alpha as a cancer immunotherapeutic”

Immunicom Inc.

HEADQUARTERS

San Diego, CA

RESOURCES

GET IN TOUCH

Your choices regarding cookies on this site

Essential Cookies

Functional Cookies

Marketing and Analytics Cookies